ATARAX CAP 10MG 10 MG — DIN 00024376
HYDROXYZINE HYDROCHLORIDE : 10 MG · ERFA CANADA 2012 INC · CAPSULE · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ATARAX CAP 10MG?
ATARAX CAP 10MG 10 MG contains HYDROXYZINE HYDROCHLORIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 00024376, held by ERFA CANADA 2012 INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 15-Sep-2005. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ATARAX CAP 10MG used for?
Management of anxiety, tension, acute emotional problems, pruritus due to allergic conditions, and control of nausea and vomiting (excluding pregnancy). IM used for acute disturbed/alcoholic patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Hydroxyzine cost around the world?
Hydroxyzine is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 5 | 72 | USD███.██ |
| South Africa | single exit price | 5 | 6 | ZAR███.██ |
| Greece | producer price (ex-factory) | 4 | 4 | EUR███.██ |
| Morocco | PPV (public price) | 1 | 3 | MAD███.██ |
| United Kingdom | hospital | 1 | 1 | GBP███.██ |
86 pack listings across 16 brand entries and 5 price bases, refreshed 05 Sep 2026. Ranges span every Hydroxyzine pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Hydroxyzine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Hydroxyzine, across 29 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AA PHARMA INC | 3 | 3 | HYDROXYZINE | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | HYDROXYZINE HYDROCHLORIDE INJECTION USP | Sourceable in Canada |
| SEARCHLIGHT PHARMA INC | 1 | 1 | ATARAX | Sourceable in Canada |
| ERFA CANADA 2012 INC | 4 | 0 | ATARAX CAP 10MG, ATARAX CAP 25MG, ATARAX CAP 50MG, ATARAX IM SOL 50MG/ML | No marketed DIN |
| PHARMASCIENCE INC | 4 | 0 | PMS HYDROXYZINE CAP 10MG, PMS HYDROXYZINE CAP 25MG, PMS HYDROXYZINE CAP 50MG, PMS HYDROXYZINE SYR 10MG/5ML | No marketed DIN |
| LABORATOIRE RIVA INC. | 3 | 0 | RIVA-HYDROXYZIN 10MG CAPSULES, RIVA-HYDROXYZIN 25MG CAPSULES, RIVA-HYDROXYZIN 50MG CAPSULES | No marketed DIN |
| NU-PHARM INC | 3 | 0 | NU-HYDROXYZINE | No marketed DIN |
| PRO DOC LIMITEE | 3 | 0 | HYDROXYZINE-10, HYDROXYZINE-25, HYDROXYZINE-50 | No marketed DIN |
| TEVA CANADA LIMITED | 3 | 0 | NOVO-HYDROXYZIN | No marketed DIN |
| RHONE-POULENC RORER CANADA INC. | 2 | 0 | MULTIPAX CAP 10MG, MULTIPAX CAP 25MG | No marketed DIN |
| FRESENIUS KABI CANADA LTD | 1 | 0 | HYDROXYZINE HYDROCHLORIDE INJECTION | No marketed DIN |
| STERIMAX INC | 1 | 0 | HYDROXYZINE HYDROCHLORIDE INJECTION, USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | Syrup: 473 mL bottles. Injection: 10 mL vials and 1 mL vials (boxes of 10). Capsules: Bottles of 100. |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Hydroxyzine |
|---|---|
| ATC code | N05BB01 |
| AHFS class | 28:24.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00024376 |
|---|---|
| DIN (unpadded, as printed on some documents) | 24376 |
| Brand name | ATARAX CAP 10MG |
| Generic / active ingredient | HYDROXYZINE HYDROCHLORIDE : 10 MG |
| Market authorization holder | ERFA CANADA 2012 INC |
| Health Canada schedule | Prescription |
| ATC code | N05BB01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05BB |
| Current status | CANCELLED POST MARKET |
| Status date | 15-Sep-2005 |
| Original market date | 1956-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Oral: Adults 25-100 mg 3-4 times daily. IM: 25-100 mg. IM must be deep intramuscular injection only; do not inject SC, IV, or intra-arterially. Narcotic doses may need 50% reduction.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known hypersensitivity to hydroxyzine hydrochloride or any component; early pregnancy; nausea and vomiting of pregnancy.
Warnings and precautions
Caution in patients with epilepsy. May cause drowsiness; caution against driving or operating machinery. IM route only; avoid SC, IV, or intra-arterial injection.
Is Hydroxyzine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by AA PHARMA INC, last seen 16 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 29 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ATARAX | 10 MG / 5 ML | SYRUP | SEARCHLIGHT PHARMA INC | MARKETED | 00024694 |
| HYDROXYZINE | 25 MG | CAPSULE | AA PHARMA INC | MARKETED | 00646024 |
| HYDROXYZINE | 50 MG | CAPSULE | AA PHARMA INC | MARKETED | 00646016 |
| HYDROXYZINE | 10 MG | CAPSULE | AA PHARMA INC | MARKETED | 00646059 |
| HYDROXYZINE HYDROCHLORIDE INJECTION USP | 50 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | 00742813 |
| ATARAX CAP 25MG | 25 MG | CAPSULE | ERFA CANADA 2012 INC | CANCELLED POST MARKET | 00024384 |
| ATARAX CAP 50MG | 50 MG | CAPSULE | ERFA CANADA 2012 INC | CANCELLED POST MARKET | 00024392 |
| ATARAX IM SOL 50MG/ML | 50 MG | SOLUTION | ERFA CANADA 2012 INC | CANCELLED POST MARKET | 00024589 |
| HYDROXYZINE HYDROCHLORIDE INJECTION | 50 MG | LIQUID | FRESENIUS KABI CANADA LTD | CANCELLED PRE MARKET | 02242864 |
| HYDROXYZINE HYDROCHLORIDE INJECTION, USP | 50 MG | SOLUTION | STERIMAX INC | DORMANT | 02231209 |
2 · Same class — other molecules in ATC N05BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Hydroxyzine | ATARAX · ATARAX CAP 10MG · ATARAX CAP 25MG · ATARAX CAP 50MG · +19 more | 29 | 5 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05BA | Alprazolam · Bromazepam · Chlordiazepoxide · Clobazam · Clorazepate Potassium · +4 more | 232 | 57 |
| N05BE | Buspirone | 25 | 7 |
| N05BC | Meprobamate | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ATARAX CAP 10MG called?
The same molecule, Hydroxyzine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ATARAX | Latin | Morocco |
| Aterax | Latin | South Africa |
| Aterax Syrup | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.